Kyoto University

Koh Ono

Haruhisa Inoue

Takahiro Horie

Akira Kakizuka

Keiko Imamura

Shigehiko Suzuki

Fumiko Nakazeki

Takeshi Kimura

Naritatsu Saitou

Motoko Naitoh

Yuya Ide

Itaru Tsuge

The inventors have found that the compounds of formula (I) protect cardiomyocytes. Accordingly, the disclosure provides a pharmaceutical composition for protecting a cardiomyocyte comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. The pharmaceutical composition may be used for treating or preventing a disease associated with cardiomyocyte death, such as myocardial infarction, chronic heart failure, hypertensive heart failure, or dilated cardiomyopathy, especially for treating myocardial infarction.

Composition for protecting cardiomyocyte

An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Composition for preventing or treating neurodegenerative disease

The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene. A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.

Therapeutic or prophylactic composition for TDP-43 proteinopathy

Growing community of inventors

Kyoto, Japan

Koh Ono